Previous 10 | Next 10 |
2024-04-04 09:21:23 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries: Potential Outweighs Concerns Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities Teva Pharmaceutical: I Need To See Top-Line Growth Return Before Starting A Pos...
Teva and mAbxience enter into a strategic global partnership for in-licensing of an oncology biosimilar candidate Agreement signals a major step in mAbxience's global expansion strategy and advances a key element of Teva’s Pivot to Growth strategy to expand its biosimilar pipeline ...
2024-04-03 08:28:03 ET More on Teva , UroGen Pharma, etc. Teva Pharmaceutical Industries: Potential Outweighs Concerns UroGen: All Eyes On UGN-102 UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript Teva and Viatris revives chance to dispute J&J's ...
2024-04-01 12:17:16 ET NYSE: TEVA NASDAQ: VTRS NYSE: JNJ More on Johnson & Johnson, Teva Pharmaceutical, etc. Viatris Stock Is Still Worth Buying With Lawsuit And Medtech Tailwinds - Johnson & Johnson May Be Back Viatris Inc. (VTRS) R&...
2024-04-01 09:05:12 ET More on Carlyle, Teva Pharmaceutical, etc. Teva Pharmaceutical Industries: Potential Outweighs Concerns Carlyle Group: A Strong Company But Trades At A Premium Carlyle: Asset-Management Tailwinds And A High Yield Carlyle Group names Lin...
Collaboration combines Teva’s expertise in respiratory technology development and Launch Therapeutics’ innovative late-stage drug development model to progress Teva’s Dual-Action Asthma Rescue Inhaler (TEV-‘248) program Development funding agreement to provide ...
2024-03-27 14:21:05 ET Teva Pharmaceutical ( NYSE: TEVA ) shares are trading in the green on Wednesday, making it the seventh straight day of gains. Stock is up 1.38% at $14.34.... Read the full article on Seeking Alpha For further details see: Teva on track for seve...
2024-03-25 14:08:26 ET Summary Teva Pharmaceutical is deeply undervalued, trading at a 77% discount per my calculations, and the new CEO's turnaround plan looks promising. Teva is an Israeli pharmaceutical company focused on affordable generic medicine, with a strong presence in N...
2024-03-11 09:43:30 ET More on Viatris Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued Viatris Inc. (VTRS) Q4 2023 Earnings Call Transcript Viatris Reduces Debt But Faces Growth Hurdles Dividend rally: Top 10 large-cap performers in 2024 ...
2024-03-08 10:21:57 ET More on Teva Pharmaceutical Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities Teva Pharmaceutical: I Need To See Top-Line Growth Return Before Starting A Position A Review Of Teva's Prospects UroGen falls as Te...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA)...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company’s manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is le...
These large-cap stocks were the best performers in the last week. Are they in your portfolio? Teva Pharmaceutical Industries (NYSE:TEVA) shares s...